Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Public ClinicalTrials.gov record NCT01030432. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
Study identification
- NCT ID
- NCT01030432
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 285 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2010 (Type not available)
- Primary completion
- Oct 2012 (Actual)
- Completion
- Oct 2012 (Actual)
- Last update posted
- Oct 9, 2015
2010 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama At Birmingham | Birmingham | Alabama | 35294-0006 | — |
| Alabama Liver & Digestive Specialists (Alds) | Montgomery | Alabama | 36116 | — |
| Florida Hospital Transplant Center | Orlando | Florida | 32804 | — |
| Mercy Medical Center | Baltimore | Maryland | 21202 | — |
| The Research Institute | Springfield | Massachusetts | 01105 | — |
| Umass Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| James J Peters Vamc | The Bronx | New York | 10468 | — |
| University Of North Carolina, Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Healthcare Research Consultants | Tulsa | Oklahoma | 74135-2920 | — |
| Oregon Health Science Univ | Portland | Oregon | 97239 | — |
| Hospital Of The University Of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Gastro One | Germantown | Tennessee | 38138 | — |
| Metropolitan Research | Fairfax | Virginia | 22031 | — |
| Dean Clinic | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01030432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2015 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01030432 live on ClinicalTrials.gov.